[Implantable intravitreal corticosteroids in chronic noninfectious uveitis]

Area of Science:

• Ophthalmology
• Pharmacology

Background:

• Uveitis causes significant vision loss, affecting 10-15% of cases in industrialized nations.
• Current treatments include local/systemic steroids and immunomodulators.
• Intravitreal corticosteroids offer an alternative for chronic or refractory uveitis, particularly with uveitic macular edema.

Purpose of the Study:

• To review current intravitreal corticosteroid implants for noninfectious uveitis.
• To discuss indications, effectiveness, and side effect profiles based on existing literature.
• To evaluate outcomes from randomized controlled studies and subgroup analyses.

Main Methods:

• Review of 6 randomized controlled studies on fluocinolone acetonide (FAc) and dexamethasone (DEX) implants.
• Inclusion of a subgroup analysis from a multicentric randomized study (315 patients).

Main Results:

• Intravitreal corticosteroids show efficacy in treating uveitic macular edema.
• Long-acting implants reduce relapse frequency and prolong remission intervals.
• Short-acting implants are suitable for managing acute uveitic episodes.

Conclusions:

• Intravitreal corticosteroids offer a viable treatment for uveitic macular edema with manageable side effects.
• Long-acting implants are beneficial for long-term disease control.
• Patient counseling regarding potential adverse effects, such as cataracts, is crucial, especially for younger or phakic patients.